Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
3(33%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
2
22%
Ph phase_1
1
11%
Ph phase_4
2
22%
Ph phase_2
2
22%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(4)

Detailed Status

Completed4
Recruiting2
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 42 (28.6%)

Trials by Status

recruiting222%
completed444%
not_yet_recruiting222%
active_not_recruiting111%

Recent Activity

3 active trials
Showing 5 of 9
active_not_recruiting

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448
completed

Registry of Asthma Patients Initiating DUPIXENT®

NCT04287621
completedphase_2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966
not_yet_recruitingphase_3

A Phase III Study of GS101 Injection to Dupixent®

NCT07386743
recruitingphase_4

Complete Remission After Treatment With Biologics for Nasal Polyps

NCT07268313
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04959448

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Active Not Recruiting
NCT04287621

Registry of Asthma Patients Initiating DUPIXENT®

Completed
NCT04502966Phase 2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Completed
NCT07386743Phase 3

A Phase III Study of GS101 Injection to Dupixent®

Not Yet Recruiting
NCT07268313Phase 4

Complete Remission After Treatment With Biologics for Nasal Polyps

Recruiting
NCT06884891Phase 3

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Not Yet Recruiting
NCT06614907Phase 1

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Completed
NCT05470114Phase 2

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Completed
NCT05285839Phase 4

Dupixent and Narrowband UVB for Atopic Dermatitis

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9